PHP206 Coverage with Evidence Development in Sweden – Formality or Effective Way to Reduce Uncertainty?  by Kornfeld, A. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A487
when and for what type of service use publicly financed health care. Methods: 
Data was retrieved from National Health Insurance Fund Administration of Hungary 
(NHIFA) and Central Statistical Office. Current study’s base was processing the last 
five years’ statistical data (2007-2012), concerning health care of third country 
citizens permanently living in Hungary. We analyzed the volume, place and medi-
cal specialty of these services. Results: In the last 5 years third country citizens 
required inpatient care 9414 times (61% in Budapest), emergency care 11776 times 
(63% in Budapest), out-patient care 72306 times (57% in Budapest). Patient accessed 
health care providers due to medical problems in the following medical fields: 
obstetrics (19%), surgery (18%), laboratory (18%), pediatrics (7%), and ophthalmol-
ogy (6%). Most of the patients are from Ukraine (42 %), China (22 %), Vietnam (11 %), 
ex-Yugoslavia (6 %) and Russia (6 %). Analysis by nationalities shows that Chinese 
population requires health care relatively few times (for instance, 2011: 5%, in 2012: 
6%) and even these are almost exclusively done in Budapest. In contrast USA citizens 
see doctors relatively often (2011: 8%, 2012: 8%), mainly in relation to diagnostics and 
curative surgery. From the neighboring non-EU states (23095 people, 31%) Ukrainian 
and (5709 people, 7%) ex-Yugoslavian citizens needed health care in the investigated 
period. Despite previous expectations, need for health care is not the characteristics 
of border regions but the capital city. ConClusions: Utilization of the Hungarian 
publicly financed health care system is significant by third country citizens. When 
planning health care capacity, this crucial fact must be taken into consideration.
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PHarmaceutical regulation in euroPe and its imPact on corPorate 
r&d
Mahlich J.1, Eger S.2
1University of Vienna, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria
objeCtives: Many European countries regulate drug prices in order to cope with 
rising health expenditures. On the other hand, price regulation distorts incentives to 
invest in pharmaceutical R&D. This study aims at empirically assessing the impact 
of price regulation on pharmaceutical R&D expenditures. Methods: We analyze 
a sample of 20 leading pharmaceutical companies between 2000 and 2008. The 
share of sales in Europe serves as a proxy for the degree of price regulation. We 
control for other determinants of R&D such as cash flow, company size, leverage 
ratio, growth rate, and Tobin’s q. Results: Our results suggest a nonlinear rela-
tionship between European sales ratio and R&D intensity. Beyond a threshold of 
33% of sales generated in Europe, a higher presence in Europe is associated with 
lower R&D investments. ConClusions: Price regulation has a negative impact 
on pharmaceutical R&D investments. Policy makers must take long term effects 
of regulation into account.
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objeCtives: This research was designed to find out the key attribute for ben-
efit-risk assessment using swing weight method in general population, health 
authority and hospital doctors. Methods: We selected six important elements 
for each benefit and risk assessment based on previous study. The elements of 
benefit assessment consisted of disease severity, size of population affected by 
disease, clinical guidelines recommendation, comparative interventions limita-
tion, improvement of efficacy/effectiveness, improvement of quality of life. The 
attributes of risk assessment contained overall incidence of adverse events, 
overall incidence of serious adverse events, discontinuation rate due to adverse 
events, drug or food interactions, drugs of potential misuse, risk management. 
583 subjects constituted 3 groups (general population, health authority and hos-
pital doctors) were selected across the country by quota sampling method and 
performed survey to evaluate preference of each elements with the swing methods 
repeatedly. The trained interviewers assisted participant successfully completed 
survey. Results: Improvement of efficacy/effectiveness and overall incidence 
of serious adverse events were revealed as the most important attributes than 
others for benefit- risk assessment in all three groups. Health authority group 
outweighed the improvement of efficacy/effectiveness [Mean (±SD): 0.208(±0.04)] 
and overall incidence of serious adverse events [Mean (±SD): 0.220(±0.05)], while 
0.204(±0.03), 0.216(±0.04) in doctor group and 0.197(±0.04), 0.185(±0.04) in general 
population respectively. In six benefit attributes, the lowest preference score was 
clinical guidelines recommendation [0.114(±0.04)] in health authority group and 
[0.144(±0.04)] in general population while size of population affected by disease 
[0.126(±0.04)] in hospital doctor group. Among six risk elements, the lowest prefer-
ence was drugs of potential misuse showed in health authority [0.117(±0.04)] and 
in hospital doctors [0.121(±0.04)] while risk management [0.121(±0.04)] in general 
population. ConClusions: This shows that improvement of efficacy/effective-
ness among benefit attributes and overall incidence of serious adverse events 
among risk attributes are key elements for benefit-risk assessment.
HealtH care use & Policy studies – risk sharing/Performance-Based  
agreements
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Kornfeld A.1, Schroeder M.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Copenhagen, Denmark, 3University Claude 
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objeCtives: TLV (formerly LFN) is responsible for reimbursement decisions in 
Sweden. They regularly give temporary reimbursement with request for additional 
ject, applicable to both single and multi-company projects. Any obligatory internal 
processes should be completed in tandem. Results: Health outcomes studies, 
pharmacoeconomic evaluations, and risk sharing agreements for the access of new 
pharmaceuticals were identified as projects of high priority to implement in the 
following years. ConClusions: The steps outlined in this guidance, although not 
compulsory, will provide useful practical tips for how to go about setting up a Joint 
Working project in Catalonia (Spain), and to assist through the remainder of it. This 
guide is not a substitute for suitable regulatory or legal advice.
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objeCtives: In the context of increasing demand and expenditure for health 
services it is important to elaborate policies which maximise efficiency. 
Pharmaceuticals account for about a fifth of total health care expenditure and are 
often target of health care efficiency policies. The aim of this study is to classify 
and grade pharmaceutical supply and demand control policies across the globe 
and cluster systems by regulatory rigidity. Methods: Pharmaceutical policies and 
market data across 65 countries were researched in the literature with emphasis 
on pricing, reimbursement, dispensing, expenditure and demand control domains. 
Policies were classified by domains and graded through a multi-country expert sur-
vey for the degree of regulation. Cluster analysis helped to group countries by policy 
types. Results: Pricing policies for on-patent products (with increasing degree 
of regulation) include: free pricing, direct negotiations, value-based-pricing, cost-
plus-pricing, conditional-pricing, reference-pricing, state dictates and tenders. Cost 
control policies include: discounts, rebates, risk-sharing agreements, price-volume 
agreements, profit controls, pay-backs, claw-backs, margin cuts, price cuts, freezes, 
and tenders. Reimbursement policies include: variants of ATC5-based internal refer-
encing, variants of statutory copayments, and variants of ATC4-based internal refer-
encing. Dispensing policies were: no restrictions, indicative substitution, mandated 
or compulsory substitution. Demand controls include: educational campaigns, 
prescription aids, indicative prescription guidelines, indicative INN prescription, 
prescription monitoring, quotas, targets, predefined budgets, compulsory INN pre-
scription, mandatory electronic prescription, compulsory prescription guidelines, 
prior/posterior approvals, sanctions and incentives for target/guidelines adherence. 
Cluster analysis identified a set of countries using an intermediate regulation policy 
approach and another with a more rigid approach. These did not differ significantly 
(p: 0.20) concerning pharmaceutical expenditure as % of GDP. ConClusions: A 
variety of policies were used in recent years for controlling pharmaceutical expen-
ditures. Countries fall into two subsets based on the intensity of the regulation. 
More regulated systems do not appear to be associated with lower pharmaceutical 
expenditure.
PHP202
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Biologicals in euroPe
Bouvy J.1, Ebbers H.2, Schellekens H.2, Koopmanschap M.A.3
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objeCtives: The safety profile of new drugs is usually not fully established upon 
market entry, giving cause for Europe’s comprehensive pharmacovigilance sys-
tem. A key regulatory vehicle to communicate the outcomes of pharmacovigilance 
activities is the Periodic Safety Update Report (PSUR), which summarizes a prod-
uct’s worldwide safety data and facilitates periodic assessment of its benefit-risk 
profile. We assessed the cost-effectiveness of all PSURs submitted in Europe during 
1995-2009 for biologicals, using a societal perspective. Methods: We evaluated 
two regulatory scenarios: Full Regulation (pharmacovigilance including PSURs) and 
Limited Regulation (pharmacovigilance without PSURs). We assessed the source 
of regulatory action for all urgent safety issues that were identified for biologicals 
during 1995-2009. In two out of 24 urgent safety issues (systemic spread of botu-
linum toxin and edema after use of dibotermin-alfa), PSURs were the regulatory 
instrument that identified the safety issue and we assumed these issues would 
have been discovered five years later under limited regulation. Estimates from the 
literature and Markov-chain life tables were used to calculate costs and effects 
of PSURs for biologicals. Results: The incremental cost-effectiveness ratio (ICER) 
of Full Regulation versus Limited Regulation was € 342,110 per quality-adjusted 
life year gained. Extensive sensitivity analyses indicated a low probability of the 
Full Regulation scenario being cost-effective. Only two parameters resulted in a 
more favorable ICER: a 100% risk reduction after identification of the urgent safety 
issues (base-case assumption was 25%) and a high risk (1 in 1,000 patients) of severe 
systemic spread after therapeutic use of botulinum toxin (base-case assumption 
1 in 10,000 patients). ConClusions: Regulatory cost-effectiveness analysis is a 
feasible instrument for assessing the (added) value of parts of the drug regulatory 
framework. In light of high costs of regulatory compliance, cost-effectiveness should 
be a consideration in deciding whether or not safety-related regulatory actions 
are required.
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utilization of tHe Hungarian PuBlicly financed HealtH care system 
By tHird (non eu) country citizens
Kovács G.1, Boncz I.2, Gyeney L.3
1Széchenyi István University, Győr, Hungary, 2University of Pécs, Pécs, Hungary, 3Pázmány Péter 
Catholic University, Budapest, Hungary
objeCtives: The number of citizens from third countries (outside of European 
Union or stateless) permanently living in Hungary is 205 000, and annually ca. 23000 
people get permit to settle. Current study aims at exploring what group of foreigners, 
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systematically collected through visiting social health insurance bureau websites, 
literature review and key informant interview. Case study and comparison analy-
sis were conducted among these schemes. Results: Two kinds of risk sharing 
schemes, performance based scheme and financial based scheme, were employed 
in sampling provinces and cities, with the latter model more often implemented. 
Performance based scheme has only been developed in one city (Guangzhou) for a 
non-small-cell lung cancer drug. Patients eligible for inclusion criteria and treated 
in one of three designated hospitals could be qualified to reimburse for more than 
one year treatment if they were responsive to the drug. Other provinces and cities 
has adopted the financial based scheme, mainly focusing on increasing patients 
access to expensive drugs, usually for breast cancer, leukemia and non-small-cell 
lung cancer and not covered by health insurance schemes. For instance, local health 
insurance fund of Zhejiang and Jiangsu province would only reimburse patients’ five 
to six months treatment and pharmaceutical company should sponsor patients’ 
treatment for the next six months. Besides, cities like Qingdao and Chengdu imple-
mented the price volume scheme for special drugs and medical materials in order to 
control fund expenditure. ConClusions: By risk sharing scheme, some innovative 
drugs, previously not covered by social health insurance, can be reimbursed, which 
will increase patients’ access, reduce patients economic burden, and help expend-
ing pharmaceutical companies’ market share. However, as risk sharing scheme in 
China has only been adopted for only one or two years, long-term impact still needs 
to be observed and evaluated.
PHP210
squaring tHe circle: innovative contracting to acHieve marKet 
access for innovative Products
Street-Docherty L.M., Morrison S.
GfK Bridgehead, Melton Mowbray, UK
In an increasingly resource-constrained environment, a variety of innovative 
contracting arrangements exist, representing an alternative to conventional pric-
ing and reimbursement agreements between payer and manufacturer. There are 
various tools and resources that may influence funding with which payers and 
prescribers would welcome support from manufacturers. objeCtives: To gain 
an overview of contractual agreements currently used within the pharmaceu-
tical sector and to uncover how innovative contracting has, and continues to, 
evolve. Methods: Secondary research was conducted to identify examples of 
innovative contracting, highlighting elements that work and associated hur-
dles, in order to understand issues relating to transparency and implementa-
tion. Results: Sixteen markets worldwide embrace innovative schemes with 
a further 5 markets beginning to show uptake. In the past, agreements were 
predominantly performance-based. However, companies are increasingly moving 
towards financial schemes such as product bundling, confidential discounts and 
fixed price treatments. The most common elements of risk-sharing agreements 
are price volume agreements (39%), requirement for data collection (29.5%), and 
access limited only to eligible patients (13.1%). Innovative contracts are predomi-
nantly used for drugs that relate to high cost or high performance with oncology 
being the therapeutic area that dominates these agreements. ConClusions: 
Innovative contracting schemes can aid manufacturers with market access, help 
to maintain price and increase usage. However, the current design of many agree-
ments is suboptimal, and there are hurdles which need to be overcome. It is 
important that there is a balance between risk and incentive for all stakeholders, 
and this balance between the benefits and cost implications must be carefully 
considered.
HealtH care use & Policy studies – conceptual Papers
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tHe HealtH of HealtH tecHnology assessment in ireland: five Points 
for imProvement
O’Mahony J.1, O’Neill C.2
1Trinity College Dublin, Dublin, Ireland, 2National University of Ireland Galway, Galway City, 
Ireland
This study critically appraises the contribution of cost-effectiveness analysis (CEA) 
in improving the rational allocation of health care resources in Ireland. While Ireland 
has successfully established some of the institutional infrastructure for CEA, there 
remain key areas for improvement: 1) Ireland has an explicit cost-effectiveness 
threshold of € 45,000/QALY. It resulted from negotiations between the pharmaceu-
tical industry and the public health service and only applies to pharmaceutical 
interventions. If Ireland is to use a threshold, it would be better served by an empiri-
cally determined threshold that applies to all interventions. 2) The threshold has 
recently been exceeded by a number of expensive drugs, in some cases by a very 
large margin. Conversely, despite being highly cost-effective, colorectal screening 
remains unimplemented due to a failure to allocate resources. In the absence of 
clarity around these decisions, the allocations appear to indicate that considera-
tions of budget impact are dominating rather than complementing those of cost-
effectiveness. 3) Recent CEAs by Ireland’s statutory health technology assessment 
authority, the Health Information and Quality Authority (HIQA), appear to confuse 
average cost-effectiveness ratios with incremental cost-effectiveness ratios (ICERs). 
Clarity around the interpretation of cost-effectiveness evidence is required to instil 
confidence in the process. 4) Ireland has an established CEA process to appraise 
new drugs. However, this process has been bypassed in recent cases, as some costly 
cancer drugs have been approved before being subject to CEA, despite recommen-
dations that these drugs be assessed. Consistency in approach is required to instil 
confidence in the process. (5) Greater transparency around reimbursement decisions 
would be desirable, whereby the relevant bodies issue documentation explaining 
their decisions and deliberations. In conclusion, CEA could make a greater contri-
bution to rational resource allocation in Ireland if more rigorous and consistent 
decision rules were applied. Greater accountability of the decision making process 
should further that goal.
data: Coverage with Evidence Development (CED). The objective of this study was 
to review the outcomes of the CEDs granted by TLV during the years 2005 to 2012, 
and to appreciate if it is an effective way to manage uncertainty. Methods: All 
decisions published from January 2005 to December 2012 on the TLV website were 
screened. All decisions that included a CED were reviewed and the information 
on the initial decision for a CED and the final decision based on the evidence 
developed were extracted in a standardized way. The information was then ana-
lyzed. Results: During the period TLV issued 38 decisions with a CED, 4 in 2012, 
5 in 2011, 11 in 2010, 3 in 2009, 2in 2008, 8 in 2007, 5 in 2006 and none in 2005. For 
10 CEDs issued 2010 to 2012 the time for evaluation had to yet been reached. For 
12 CED decision taken from 2006 to 2010 the time for evaluation was reached but 
no decision had been taken and the products continue to be reimbursed accord-
ing to the conditions in the temporary reimbursement decision. 7 products were 
granted general reimbursement and 9 limited reimbursement based on the evalu-
ation of the evidence. No product was rejected reimbursement. ConClusions: 
Although it is early to draw any final conclusions, a significant number of CED 
decisions were not followed up with a final decision, which leads to continued 
reimbursement. The risk of de-reimbursement based on a CED seems minimal in 
Sweden. Therefore it is unclear if CED will actually contribute to manage uncer-
tainty in Sweden.
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variances in individuals’ PrescriPtion drug costs in ireland
Walshe V.1, Kenneally M.2, Buckley G.2
1Health Service Executive, Cork, Ireland, 2University College Cork, Cork, Ireland
objeCtives: To assess the average individual’s drug costs prescribed under the 
main community drug scheme in Ireland over time, by age cohort and by geo-
graphical region. It also examined regional costs having standardized for age and 
sex. Methods: The 2002 to 2012 average pharmacy payment per eligible person, 
number of items prescribed per person and the average cost per item prescribed 
were calculated. The most recent average individual cost of medicines was exam-
ined for each of the 4 health regions and 32 sub-regions by 22 age and sex cohorts. 
Regional age and sex adjustments were made by applying the scheme’s national 
age and sex weights to each region’s costs. This produced regional cost estimates 
independent of age and sex variations. Results: Community drug expenditure 
has undergone substantial growth in the past 10 years with costs more than dou-
bling and the number of persons covered by the main scheme increasing by nearly 
60%. Nationally an individual’s average cost of medicines was € 713 in 2011, varying 
from € 670 (-6%) in HSE-West to € 762 (+7%) in HSE-South. Sub-regional LHO (local 
health office) cost variances were significantly greater ranging from € 200 to € 1,200. 
Average cost increases with age and for persons over 75 was nearly 4 times those 
aged 35 to 44 (€ 1,689 versus € 446). Removing the impact of age and sex increases 
cost variances marginally overall, restraining some regions costs and promoting 
others. ConClusions: Individuals’ prescription drug costs vary significantly by 
age and sex however regional cost differences are not explained by variances in age 
and sex and may be a result of other factors such as prevalence of chronic health 
conditions and GP prescribing patterns.
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analysis and classification of risK-sHaring scHemes ProPosed in 
reimBursement aPPlication received By aHtaPol in 2012
Zawodnik S.1, Iwanczuk T.1, Hermanowski T.2, Matusewicz W.3
1Agency for Health Technology Assessment in Poland, Warsaw, Poland, 2Department of 
Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 3Agency for Health 
Technology Assessment in Poland (AOTM), Warsaw, Poland
objeCtives: To analyze and classify the Risk-Sharing Schemes (RSSs) proposed in 
reimbursement applications received by Agency for Health Technology Assessment 
in Poland (AHTAPol) in 2012. Methods: Risk-Sharing Schemes proposed in reim-
bursement applications received by AHTAPol in 2012 were quantitatively and 
qualitatively analyzed. The classification of the RSSs was also conducted based 
on both Carlson’s approach and the Polish Act on Reimbursement of medicinal 
products. Results: In the studied period, 52 reimbursement applications with 26 
proposed RSSs were received by AHTAPol. They were classified into 5 categories 
according to the Act on Reimbursement. The most common category was making 
the official sales price dependent on the applicant providing supplies at a reduced 
price, as specified in the negotiations on the price of the medicine (34.61%). Further 
categories were: making the official sales price dependent ona pay-back of a part 
of the reimbursement obtained to the entity which is obliged to finance bene-
fits with public funds (23.08%), making the official sales price dependent on the 
level of turnover of the medicine (11.54%) and making the level of the applicant’s 
revenues dependent on the health effects achieved (3.85%). RSSs classified as 
others constituted 26.92% of all. Among 26 proposed RSSs only 8 of them could be 
classified according to the Carlson’s approach (1 proposition included more than 
one category). As a results, 4 Price Volume Agreements, 4 Manufacturer Funded 
Treatment Initiation and 1 Conditional Treatment Continuationwere identi-
fied. ConClusions: Most of the propositions should not be considered as RSS 
according to the Carlson’s approach. The most common propositions were related 
to medicinal product’s price reduction and did not include any risk sharing. There 
is a strong need for further research.
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risK sHaring for innovative PHarmaceuticals witHin social HealtH 
insurance: exPeriences from cHina
Chen W.1, Zhang L.1, Fan W.2
1Fudan University, Shanghai, China, 2School of Public Health, Fudan University, Shanghai, China
objeCtives: To understand current risk sharing scheme landscape for innova-
tive pharmaceuticals in some typical provinces and cities of China. Methods: 
Risk sharing schemes for pharmaceuticals in four provinces (Guangdong, Zhejiang, 
Jiangsu and Sichuan) and three cities (Guangzhou, Hangzhou and Chengdu) were 
